References
Original article
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet https://doi.org/10.1016/S0140-6736(23)02268-7 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. Personalized neoantigen mRNA vaccine mitigates melanoma recurrence. Nat Rev Clin Oncol 21, 168 (2024). https://doi.org/10.1038/s41571-024-00867-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-024-00867-1
- Springer Nature Limited